Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease)

Processes

Edward Richardson¹  Kyle S. Gabrick¹  John A. Persing¹  Henry C. Hsia¹  Kaiti Duan¹  Hassan Peyvandi¹  Biraja C. Dash¹  Sifon U. Ndon¹  Athena A. Faz²  Alan Dardik³ 

[1] Department of Surgery, Section of Plastic Surgery, Yale University School of Medicine, PO Box 208041, New Haven, CT 06520-8041, USA;Hearing Disorders Research Center, Loghman Hakim Medical Center, Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran;Vascular Biology and Therapeutics Program and The Department of Surgery, Yale School of Medicine, Yale University, New Haven, CT 06519, USA;

关键词: thromboangiitis obliterans;    inflammation;    angiogenesis;    immunomodulation;    pluripotent stem cell;    mesenchymal stem cell;   

DOI  :  10.3390/pr8111408

来源: DOAJ

【 摘 要 】

Buerger’s disease or Thromboangiitis Obliterans (TAO) is a nonatherosclerotic segmental vascular disease which affects small and medium arteries and veins in the upper and lower extremities. Based on pathological findings, TAO can be considered as a distinct form of vasculitis that is most prevalent in young male smokers. There is no definitive cure for this disease as therapeutic modalities are limited in number and efficacy. Surgical bypass has limited utility and 24% of patients will ultimately require amputation. Recently, studies have shown that therapeutic angiogenesis and immunomodulatory approaches through the delivery of stem cells to target tissues are potential options for ischemic lesion treatment. In this review, we summarize the current knowledge of TAO treatment and provide an overview of stem cell-based treatment modalities.

【 授权许可】

Unknown